Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MarzAA (marzeptacog alfa [activated])
MarzAA · 1 trial · 6 indications
| Name | Type | Description |
|---|---|---|
| MarzAA (marzeptacog alfa [activated]) | BIOLOGICAL | Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant) |
Top 8 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 15 | PHASE3 | Concizumab, Mim8, Denecimig, NNC0442-0344 A, turoctocog alfa pegol |
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Fitusiran, efanesoctocog alfa |
| Pfizer Inc. | PFE | 8 | PHASE3 | Fidanacogene elaparvovec, Marstacimab |
| BioMarin Pharmaceutical Inc. | BMRN | 2 | PHASE3 | Valoctocogene roxaparvovec |
| Hoffmann-La Roche | RHHBY | 8 | PHASE3 | Emicizumab, NXT007, SPK-8011QQ, SPK-8011, SPK-8016 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | REGV131, LNP1265 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE1 | AskBio009 |
| Bayer | BAYRY | 6 | - | Damoctocog-alfa-pegol |
MarzAA is being developed for the treatment of hemophilia A, a bleeding disorder caused by a deficiency in clotting factor VIII. It is also being studied in hemophilia B and in patients with or without inhibitors. It is an investigational therapy and has not been approved for commercial use.
MarzAA is being developed by Gyre Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol GYRE. The company is responsible for the clinical development of the drug candidate.
MarzAA is in Phase 1 clinical development. A single Phase 1 trial has been completed to evaluate the drug in adult subjects with hemophilia. It remains an investigational therapy and has not received regulatory approval.
MarzAA has been evaluated in one completed Phase 1 clinical trial, NCT04072237, titled "Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia." The trial enrolled 11 participants and included patients with hemophilia A and B, with or without inhibitors.
Yes, MarzAA is an abbreviation for marzeptacog alfa (activated). The full name is often written as MarzAA (marzeptacog alfa [activated]). Both names refer to the same investigational drug candidate being developed by Gyre Therapeutics.